2017年中国临床肿瘤学会年会结直肠癌研究进展解析  

Advances in colorectal cancer research from 2017 annual meeting of Chinese Society of Clinical Oncology

作　　者：朱德祥[1] 许剑民[1] 

机构地区：[1]复旦大学附属中山医院结直肠癌中心复旦大学附属中山医院结直肠外科,上海200032

出　　处：《中华消化外科杂志》2017年第11期1101-1104,共4页Chinese Journal of Digestive Surgery

基　　金：国家自然科学基金面上项目（81472228）;国家自然科学基金青年项目（81602036）

摘　　要：第20届全国临床肿瘤学大会暨2017年中国临床肿瘤学会（CSCO）年会于2017年9月26—30日在厦门举行，其中结直肠癌领域研究进展颇多，主要包括：（1）国产新药呋喹替尼和日本口服组合抗肿瘤药物TAS-102分别用于三线治疗晚期结直肠癌的多中心Ⅲ期临床试验FRESCO和TERRA研究均达到主要终点，明显改善总体生存。（2）mFOLFOXIRI方案新辅助化疗联合选择性放疗。以及高强度新辅助放化疗均可改善局部进展期直肠癌患者短期结局。且临床病理特征因素可用于预测病理学完全缓解。（3）septin9甲基化（mSEPT9）阳性筛查无症状老年人群结直肠癌特异度较低，但mSEPT9阴性预测非结直肠癌概率较高。且肠道微生物组学与代谢组学组合标志物有望成为结直肠癌诊断标志物。（4）肝转移灶免疫学分级适合预测行肝转移灶切除术后患者预后．右半结肠癌和左半结肠癌的免疫特征差异可解释分子靶向药物疗效差异。这些进展将有助于极大促进结直肠癌临床工作发展。There are several progresses in colorectal cancer research from 2017 annual meeting of Chinese Society of Clinical Oncology （CSCO）. （1） Phase Ⅲ multi-center trial FRESCO and TERRA study have showed domestic new drug Fruquintinib and Japanese oral combination anti-cancer drug TAS-102 significantly improved overall survival （0S） comparing to placebo in third-line metastatic colorectal cancer （mCRC） patients. （2） Preoperative neoadjuvant chemotherapy with mFOLFOXIRI and selective radiotherapy or concomitant boost neoadjuvant chemoradiotherapy （nCRT） followed by one cycle of XELOX, can improve short-term outcome for locally advanced rectal cancer, and clinical and pathological features can be used to predict complete response following nCRT. （3） In asymptomatic elderly population, the specificity of septin9 methylation detection in plasma cfDNA as colorectal cancer screening is low, but the probability of negative predictions as non-colorectal cancer is high. And integrated signature of the gut microbiome and metabolome serves as diagnostic biomarkers in patients with colorectal cancer. （d） Immunoscore system predicts prognosis after liver metastasectomy in colorectal metastases, and the immune signature difference between right and left colon cancer could explain the difference of targeted therapy.

关 键 词：结直肠肿瘤 三线治疗 新辅助放化疗 筛查 免疫特征 

分 类 号：R735.34[医药卫生—肿瘤]